Welcome to our dedicated page for Vistagen Therapeutics news (Ticker: VTGN), a resource for investors and traders seeking the latest updates and insights on Vistagen Therapeutics stock.
Vistagen Therapeutics, Inc. (symbol: VTGN) is a pioneering biotechnology firm committed to improving the lives of patients with central nervous system (CNS) disorders. The company leverages its advanced stem cell technology platform, which is based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed human cells. This innovative platform enables the creation of novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue, and cell therapy, providing clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
At the clinical stage, Vistagen is actively involved in developing and commercializing a robust pipeline consisting of six product candidates. Five of these candidates are clinical-stage investigational agents known as pherines, which represent a new class of drugs. Notable products within their portfolio include:
- PH94B: A novel neuroactive nasal spray designed to treat social anxiety disorder.
- PH10: An odorless, fast-acting synthetic neurosteroid aimed at addressing major depressive disorder (MDD).
- AV-101: An oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR), which is being developed to treat MDD, suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.
Vistagen's innovative approach and dedication to CNS disorders position it as a significant player in the biotechnology sector. The company is continually making strides in its research and clinical trials, striving to bring groundbreaking therapies to market. Investors and stakeholders can look forward to Vistagen's ongoing developments and potential future successes as it targets unmet medical needs with its cutting-edge technologies and therapeutic candidates.
VistaGen Therapeutics (NASDAQ: VTGN) has announced that Chief Executive Officer, Shawn Singh, will participate in a fireside chat with Jefferies analyst Andrew Tsai at the Jefferies Virtual London Healthcare Conference on November 18, 2021. The company focuses on developing innovative medicines for anxiety, depression, and other central nervous system disorders. A webcast of the presentation will be available on VistaGen's website for 30 days post-conference, emphasizing their commitment to advancing treatments beyond current standards of care.
VistaGen Therapeutics (NASDAQ: VTGN) announced progress in its ongoing PALISADE Phase 3 clinical trials for PH94B, aimed at treating social anxiety disorder (SAD). The company initiated a second Phase 3 trial, PALISADE-2, and reported increased R&D expenses of $10.1 million due to advancements in clinical programs. While the revenue rose slightly to $0.4 million, the net loss for the quarter reached $12.8 million. VistaGen remains committed to expanding PH94B's potential beyond SAD, with a focus on adjustment disorder with anxiety (AjDA) and other anxiety indications.
VistaGen Therapeutics (NASDAQ: VTGN) announced a conference call and webcast to discuss its Q2 financial results for FY 2022. This event will take place on November 10, 2021, at 5:00 p.m. ET. The call will review the company's financial performance for the quarter ending September 30, 2021, alongside recent achievements and future milestones. Interested parties can join via U.S. or international dial-in or through a live audio webcast. VistaGen focuses on developing innovative treatments for anxiety, depression, and other CNS disorders.
VistaGen Therapeutics (NASDAQ: VTGN) has initiated a Phase 2A clinical trial for PH94B, targeting Adjustment Disorder with Anxiety (AjDA), while concurrently advancing its Phase 3 studies for Social Anxiety Disorder (SAD). This randomized, double-blind study will enroll around 40 adults in Boston and New York, measuring anxiety changes using the Hamilton Anxiety Rating Scale. PH94B is an investigational nasal spray that aims for rapid anti-anxiety effects without systemic uptake or benzodiazepine-like side effects.
VistaGen Therapeutics (NASDAQ: VTGN) announced promising results from a preclinical study on its investigational drug PH94B, which may offer a new mechanism of action for treating anxiety without the risks associated with benzodiazepines. The study revealed that PH94B is primarily confined to the nasal passages with minimal presence in the brain, suggesting limited systemic exposure. This aligns with previous findings that it does not activate GABA-A receptors. The ongoing PALISADE Phase 3 Program aims to establish PH94B as a fast-acting treatment option for over 23 million Americans suffering from Social Anxiety Disorder.
VistaGen Therapeutics (NASDAQ: VTGN) has initiated PALISADE-2, a Phase 3 clinical trial evaluating PH94B as a rapid treatment for adults with social anxiety disorder (SAD). This randomized, multi-center, double-blind study aims to replicate findings from PALISADE-1 and a prior Phase 2 trial, which showed significant anxiety reduction within 15 minutes (p=0.002). Approximately 208 patients will participate across 15 sites in the U.S. Successful outcomes may lead to a New Drug Application to the FDA in 2023.
VistaGen Therapeutics (NASDAQ: VTGN) announced participation in Baird’s 2021 Global Healthcare Conference on September 14, 2021, at 12:10 p.m. PT. CEO Shawn Singh will lead a fireside chat and engage in one-on-one meetings during the two-day event. A live webcast of the presentation will be available on the Investors section of VistaGen's website. The company focuses on developing innovative medicines for anxiety, depression, and other CNS disorders, with three drug candidates currently showing promise in clinical studies.
VistaGen Therapeutics (NASDAQ: VTGN) reported its Q1 fiscal 2022 results, highlighting progress in its PALISADE Phase 3 Program for PH94B aimed at treating social anxiety disorder. The PALISADE-1 study is on track, with topline data expected by mid-2022. The company has also received FDA approval for an exploratory Phase 2A study targeting adjustment disorder with anxiety. Financially, revenue increased to $0.4 million, while net loss rose to approximately $7.7 million, reflecting higher R&D expenses of $5.6 million. Cash on hand stands at approximately $97.8 million.
VistaGen Therapeutics (NASDAQ: VTGN) announced a conference call on August 12, 2021, at 2:00 pm PT to discuss its financial results for the fiscal year 2022 first quarter, which ended June 30, 2021. CEO Shawn Singh and the management team will provide updates on the company’s developments and milestones during this period, along with future goals. The call is open to the public, and a live audio webcast will be available. Investors can also access a playback of the call after it concludes.
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company focused on innovative medicines for anxiety and depression, will participate in the Canaccord Genuity 41st Annual Growth Conference. The event includes a fireside chat with CEO Shawn Singh on August 11 at 1:30 p.m. PT. VistaGen will also engage in one-on-one meetings throughout the conference. A live webcast of the presentation will be available on the company's website. VistaGen’s drug candidates have shown promise in clinical studies and aim to advance treatment options for CNS disorders.
FAQ
What is the current stock price of Vistagen Therapeutics (VTGN)?
What is the market cap of Vistagen Therapeutics (VTGN)?
What does Vistagen Therapeutics, Inc. specialize in?
What is the company's main technological focus?
What are pherines?
Can you name some of Vistagen Therapeutics' key products?
What is PH94B used for?
What is PH10?
What conditions is AV-101 aimed at treating?
How does Vistagen's stem cell technology benefit drug development?
Is Vistagen Therapeutics currently in the clinical stage?
Where can I find the latest news about Vistagen Therapeutics, Inc.?
